Ovid Soars Following Encouraging Findings from Epilepsy Research
Stock Performance: Ovid Therapeutics' stock rose 24% in premarket trading following positive results from an early-stage study of its experimental drug, OV329, for drug-resistant epilepsy.
Study Results and Future Plans: The study indicated that OV329 effectively inhibits GABA-AT with a favorable safety profile, leading Ovid to plan a Phase 2a trial for focal onset seizures and a final study for its oral KCC2 activator, OV4071, expected to support regulatory submissions by early 2026.
Trade with 70% Backtested Accuracy
Analyst Views on OVID
About OVID
About the author
Ovid Therapeutics Advances KCC2 Oral Activator OV4071 Clinical Trial Plans
- Successful Safety Evaluation: The Phase 1 study of OV350 in 16 healthy participants demonstrated a good safety profile with no treatment-related serious adverse events, indicating its potential for future clinical applications in KCC2 activator development.
- Pharmacokinetics as Expected: The pharmacokinetic results for OV350 were as predicted, supporting further research into KCC2 activators, particularly the clinical trial plans for OV4071.
- Clinical Trial Plans: Ovid plans to submit a regulatory application for a Phase 1/1b clinical trial of OV4071 in Q1 2026, targeting psychosis associated with Parkinson's disease and Lewy body dementia, addressing a high unmet need.
- Investment in Drug Development: Ovid is prioritizing resources to accelerate the development of oral KCC2 activators, reflecting the company's commitment to new mechanism drugs that could open new avenues in the treatment of neuropsychiatric disorders.
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer to Advance CNS Drug Development
- New Chief Medical Officer: Ovid Therapeutics has appointed Dr. Petra Kaufmann as Chief Medical Officer, responsible for guiding clinical, medical, and regulatory strategies to advance the company’s pipeline of potential best- and first-in-class therapeutic candidates for neuronal imbalance.
- Extensive Drug Development Experience: Dr. Kaufmann brings a wealth of experience in CNS therapeutics, having served as CMO at Vigil Neuroscience and Novartis Gene Therapies, where she played a key role in the global approval of Zolgensma®, showcasing her expertise in developing drugs for complex neurological conditions.
- Patient-Focused R&D Philosophy: Dr. Kaufmann emphasizes a patient-focused development approach, committed to advancing OV329 and the KCC2 portfolio through rigorous scientific mechanisms, ensuring that each program is guided by sound clinical principles and a deep understanding of patient needs.
- Strategic Leadership Team Enhancement: Ovid's President Meg Alexander stated that Dr. Kaufmann's appointment will strengthen the company’s R&D organization, driving innovation and enhancing market competitiveness in the field of neurological therapeutics.
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer to Advance CNS Drug Development
- Leadership Enhancement: Ovid Therapeutics has appointed Dr. Petra Kaufmann as Chief Medical Officer, who will guide clinical, medical, and regulatory strategies to advance the company's clinical pipeline of potential best- and first-in-class therapeutic candidates for neuronal imbalance.
- Extensive Experience: Dr. Kaufmann brings a wealth of experience in CNS therapeutics from her previous roles at Vigil Neuroscience and Novartis Gene Therapies, where she played a key role in the global approval of Zolgensma®, which is expected to significantly enhance Ovid's R&D capabilities.
- Patient-Focused Development: Emphasizing a patient-centered approach, Dr. Kaufmann is dedicated to advancing therapies for complex neurological conditions, aligning closely with Ovid's mission and potentially accelerating the progress of its GABA-AT inhibitor, OV329.
- Strategic Collaboration Outlook: Ovid looks forward to collaborating with Dr. Kaufmann to leverage her regulatory experience and clinical principles to advance its broad portfolio of KCC2 direct activators, thereby enhancing the company's competitiveness in the CNS drug market.
Ovid Therapeutics Appoints Petra Kaufmann as Chief Medical Officer
Appointment Announcement: Ovid Therapeutics Inc. has appointed Petra Kaufmann as its new chief medical officer.
Professional Background: Kaufmann has significant experience in the biopharmaceutical sector and previously led rare-disease research initiatives at the U.S. National Institutes of Health.
Previous Role: Before joining Ovid, she was the Chief Medical Officer at Vigil Neuroscience, which was recently acquired by Sanofi.
Expertise Areas: In her previous role, Kaufmann managed various functions including medical, clinical, biomarker, patient advocacy, and regulatory aspects.
HC Wainwright & Co. Reaffirms Buy Rating for Ovid Therapeutics and Increases Price Target to $2
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Intelligence: Benzinga Pro is positioned as a source for the fastest and most accurate stock market intelligence available.
Alto Neuroscience Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday
Analyst Coverage Initiations: BTIG analyst Thomas Shrader initiated coverage on Alto Neuroscience (ANRO) with a Buy rating and a price target of $27, while B of A Securities analyst Travis Steed gave Masimo Corporation (MASI) a Neutral rating with a target of $162.
Ovid Therapeutics and Vivos Therapeutics Ratings: Leerink Partners analyst Marc Goodman rated Ovid Therapeutics (OVID) as Outperform with a price target of $5, and HC Wainwright & Co. analyst Yi Chen rated Vivos Therapeutics (VVOS) as Buy with a target of $7.
TAT Technologies Coverage: Benchmark initiated coverage on TAT Technologies Ltd. (TATT) with a Buy rating and a price target of $53.
Current Stock Prices: As of Friday, Alto Neuroscience closed at $12.11, Masimo at $151.12, Ovid at $1.3050, Vivos at $2.34, and TAT Technologies at $40.04.
Ovid Therapeutics Advances KCC2 Oral Activator OV4071 Clinical Trial Plans
- Successful Safety Evaluation: The Phase 1 study of OV350 in 16 healthy participants demonstrated a good safety profile with no treatment-related serious adverse events, indicating its potential for future clinical applications in KCC2 activator development.
- Pharmacokinetics as Expected: The pharmacokinetic results for OV350 were as predicted, supporting further research into KCC2 activators, particularly the clinical trial plans for OV4071.
- Clinical Trial Plans: Ovid plans to submit a regulatory application for a Phase 1/1b clinical trial of OV4071 in Q1 2026, targeting psychosis associated with Parkinson's disease and Lewy body dementia, addressing a high unmet need.
- Investment in Drug Development: Ovid is prioritizing resources to accelerate the development of oral KCC2 activators, reflecting the company's commitment to new mechanism drugs that could open new avenues in the treatment of neuropsychiatric disorders.
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer to Advance CNS Drug Development
- New Chief Medical Officer: Ovid Therapeutics has appointed Dr. Petra Kaufmann as Chief Medical Officer, responsible for guiding clinical, medical, and regulatory strategies to advance the company’s pipeline of potential best- and first-in-class therapeutic candidates for neuronal imbalance.
- Extensive Drug Development Experience: Dr. Kaufmann brings a wealth of experience in CNS therapeutics, having served as CMO at Vigil Neuroscience and Novartis Gene Therapies, where she played a key role in the global approval of Zolgensma®, showcasing her expertise in developing drugs for complex neurological conditions.
- Patient-Focused R&D Philosophy: Dr. Kaufmann emphasizes a patient-focused development approach, committed to advancing OV329 and the KCC2 portfolio through rigorous scientific mechanisms, ensuring that each program is guided by sound clinical principles and a deep understanding of patient needs.
- Strategic Leadership Team Enhancement: Ovid's President Meg Alexander stated that Dr. Kaufmann's appointment will strengthen the company’s R&D organization, driving innovation and enhancing market competitiveness in the field of neurological therapeutics.
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer to Advance CNS Drug Development
- Leadership Enhancement: Ovid Therapeutics has appointed Dr. Petra Kaufmann as Chief Medical Officer, who will guide clinical, medical, and regulatory strategies to advance the company's clinical pipeline of potential best- and first-in-class therapeutic candidates for neuronal imbalance.
- Extensive Experience: Dr. Kaufmann brings a wealth of experience in CNS therapeutics from her previous roles at Vigil Neuroscience and Novartis Gene Therapies, where she played a key role in the global approval of Zolgensma®, which is expected to significantly enhance Ovid's R&D capabilities.
- Patient-Focused Development: Emphasizing a patient-centered approach, Dr. Kaufmann is dedicated to advancing therapies for complex neurological conditions, aligning closely with Ovid's mission and potentially accelerating the progress of its GABA-AT inhibitor, OV329.
- Strategic Collaboration Outlook: Ovid looks forward to collaborating with Dr. Kaufmann to leverage her regulatory experience and clinical principles to advance its broad portfolio of KCC2 direct activators, thereby enhancing the company's competitiveness in the CNS drug market.
Ovid Therapeutics Appoints Petra Kaufmann as Chief Medical Officer
Appointment Announcement: Ovid Therapeutics Inc. has appointed Petra Kaufmann as its new chief medical officer.
Professional Background: Kaufmann has significant experience in the biopharmaceutical sector and previously led rare-disease research initiatives at the U.S. National Institutes of Health.
Previous Role: Before joining Ovid, she was the Chief Medical Officer at Vigil Neuroscience, which was recently acquired by Sanofi.
Expertise Areas: In her previous role, Kaufmann managed various functions including medical, clinical, biomarker, patient advocacy, and regulatory aspects.
HC Wainwright & Co. Reaffirms Buy Rating for Ovid Therapeutics and Increases Price Target to $2
Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.
Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.
Market Intelligence: Benzinga Pro is positioned as a source for the fastest and most accurate stock market intelligence available.
Alto Neuroscience Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday
Analyst Coverage Initiations: BTIG analyst Thomas Shrader initiated coverage on Alto Neuroscience (ANRO) with a Buy rating and a price target of $27, while B of A Securities analyst Travis Steed gave Masimo Corporation (MASI) a Neutral rating with a target of $162.
Ovid Therapeutics and Vivos Therapeutics Ratings: Leerink Partners analyst Marc Goodman rated Ovid Therapeutics (OVID) as Outperform with a price target of $5, and HC Wainwright & Co. analyst Yi Chen rated Vivos Therapeutics (VVOS) as Buy with a target of $7.
TAT Technologies Coverage: Benchmark initiated coverage on TAT Technologies Ltd. (TATT) with a Buy rating and a price target of $53.
Current Stock Prices: As of Friday, Alto Neuroscience closed at $12.11, Masimo at $151.12, Ovid at $1.3050, Vivos at $2.34, and TAT Technologies at $40.04.
